LAG3 and neoplasm: Also, XmAb®22841 (a bispecific antibody that simultaneously targets immune checkpoint receptors CTLA-4 and LAG-3 to promote tumor-selective T-cell activation) has been evaluated in the DUET-4 trial in combination with pembrolizumab (ClinicalTrials.gov Identifier: NCT03849469).